Novel antibodies against GPIba inhibit pulmonary metastasis by affecting vWF-GPIba interaction

Yingxue Qi¹, Wenchun Chen², Xinyu Liang¹, Ke Xu³, Xiangyu Gu¹, Fengying Wu⁴, Xuemei Fan⁵, Shengxiang Ren⁴, Junling Liu⁵, Jun Zhang⁶, Renhao Li², Jianwen Liu¹* and Xin Liang¹*

Abstract

Background: Platelet glycoprotein Ibα (GPIba) extracellular domain, which is part of the receptor complex GPIb-IX-V, plays an important role in tumor metastasis. However, the mechanism through which GPIba participates in the metastatic process remains unclear. In addition, potential bleeding complication remains an obstacle for the clinical use of anti-platelet agents in cancer therapy.

Methods: We established a series of screening models and obtained rat anti-mouse GPIba monoclonal antibodies (mAb) 1D12 and 2B4 that demonstrated potential value in suppressing cancer metastasis. To validate our findings, we further obtained mouse anti-human GPIba monoclonal antibody YQ3 through the same approach.

Results: 1D12 and 2B4 affected the von Willebrand factor (vWF)-GPIba interaction via binding to GPIba aa 41-50 and aa 277-290 respectively, which markedly inhibited the interaction among platelets, tumor cells, and endothelial cells in vitro, and reduced the mean number of surface nodules in the experimental and spontaneous metastasis models in vivo. As expected, YQ3 inhibited lung cancer adhesion and demonstrated similar value in metastasis. More importantly, for all three mAbs in our study, none of their Fabs induced thrombocytopenia.

Conclusion: Our results therefore supported the hypothesis that GPIba contributes to tumor metastasis and suggested potential value of using anti-GPIba mAb to suppress cancer metastasis.

Keywords: GPIba, vWF, Platelets, Antibody, Metastasis

Background

The association between elevated platelet number and malignant tumors was initially reported in 1872 [1, 2] and has been demonstrated in several common cancers [3–6]. Tumor cells are capable of activating and aggregating platelets to form tumor thrombus—a process referred to as tumor cell-induced platelet aggregation (TCIPA) [7]. Extensive evidence indicates that the formation of tumor thrombus contributes to critical steps in cancer metastasis, including shielding cancer cells from physiological clearance and immune surveillance and facilitating the migration, invasion, and arrestment of tumor cells within the vasculature [2, 8]. It is increasingly recognized that the formation of tumor thrombus involving platelets is the first and one of the most important steps in cancer metastasis.

Two important platelet membrane receptors, glycoprotein Ib-IX-V (GPIb-IX-V) and glycoprotein IIb-IIIa (GPIIb-IIIa, also known as integrin αIIbβ3), are essential for tumor cell-platelet adhesion and aggregation when tumor cells invade into vasculature [2]. An increasing number of studies have focused on the role of platelet membrane receptors in tumor metastasis [7, 9–11]. Although it is generally believed that the deficiency of GPIIb-IIIa or blockade of GPIIb-IIIa by monoclonal
antibodies may lead to severe bleeding complications [11], which is the main reason to limit the clinical use of these anti-GPIIIb-IIIa agents in cancer therapy, the anti-metastatic agent anti-GPIIIa49-66 scFv Ab A11 that has a slight effect on platelet count and vein bleeding time was found to have therapeutic potential in metastasis [7, 12]. While the mechanism of GPIIb-IIIa involvement in tumor metastasis is largely clarified, the role of another important adhesion receptor GPIb-IX-V in metastasis remains debatable [13]. Here, we evaluated the role of GPIb-IX-V and its therapeutic potential in metastasis.

The GPIb-IX-V complex consists of four subunits: GPIbα, GPIbβ, GPIX, and GPV. It interacts with many important extracellular ligands. GPIbα is the largest and most important component of the complex. The N-terminal domain of GPIbα contains the binding sites for several molecules, including vWF [14], P-selectin (CD62P) [15], and thrombin [16], which are essential for primary hemostasis and blood coagulation. The interaction between vWF and GPIbα was found to be particularly critical in the formation of thrombus [17]. Although there are studies that showed that knocking out the mouse GPIbα or replacing mouse GPIbα extracellular domain could significantly inhibit tumor cell metastasis [18], the deletion of GPIbα extracellular domain unfortunately induced platelet depletion, leading to severe bleeding complications [18]. In addition, blockage of GPIbα by monoclonal antibody p0p/B did not have the same influence on tumor metastasis as GPIbα knock out models [9], raising the concern if GPIbα truly participates in the metastatic process. To address this question, we screened out three anti-GPIbα mAbs with minimal effect on platelet activation as the tools to dissect the therapeutic value of GPIbα in cancer metastasis.

**Methods**

**Materials and animals**

Platelet agonist ADP and collagen (equine tendon) were from HELENA laboratories (USA). Ristocetin was from Sigma (R7752, USA). Anti-human GPIbα monoclonal antibody S22, VM16d, and AK2 were from GenTex (TX28822, USA), YO Proteins (656, USA), and Bio-Rad (MCA740T, USA), respectively. Secondary antibody anti-human/mouse CD42a Ab (MBS9206081, MyBioSource). After washing three times, the wells were blocked with 2% (w/v) BSA-PBS for 2 h. The wells were then incubated with lysate of human or mouse platelets for 2 h. After that, hybridoma supernatants or purified mAbs were added to the wells and incubated for 60 min. The bound antibodies were detected by HRP-conjugated goat anti-mouse IgG or goat anti-rat IgG. After the background signal had been subtracted, the binding curve was fitted to the eq. $Y = B_{max} \times [\text{ligand}]/(K_d + [\text{ligand}])$

where $Y$ is the specific binding, $[\text{ligand}]$ the ligand concentration, $B_{max}$ the binding maximum, and $K_d$ the equilibrium dissociation constant.

The specificities of the antibodies were also determined by Western blot as previously described [21].

**Preparation of Fab fragment**

The generation of Fab fragment was following previously described protocol with the modification in incubation time with immobilized papain (20341, Thermo Scientific) [21]. After papain was removed via centrifugation, the

**Human blood collection**

Written, informed consent was obtained from all participants prior to their inclusion in studies. Venous blood was collected from healthy adult volunteers at East China University of Science and Technology, as well as lung cancer patients at Shanghai Pulmonary Hospital. In addition, the use of donor-derived human platelets was approved by IRB in Shanghai Pulmonary Hospital.

**Production and characterization of GPIbα mAbs**

Rat anti-mouse GPIbα monoclonal antibodies and mouse anti-human GPIbα monoclonal antibodies were prepared according to the methods described by Koehler and Milstein [20]. Briefly, to develop mouse anti-human antibodies, BALB/C female mouse (6 to 8 weeks) were immunized by four injections of human platelet lysate at a 28-day interval. To develop rat anti-mouse antibodies, Wistar female rats were given an intraperitoneal injection of washed mouse platelets four times at a 20-day interval. Three days after the fourth immunization, mouse or rat splenocytes were fused with Sp2/0-Ag14 myeloma cells and cultured in HAT selection medium. IgGs were purified from hybridoma supernatants using a protein G-Sepharose 4B column (6518-1, Biovision, CA, USA).

The ELISA assay was then used to characterize these antibodies. Ninety-six well microtiter plates were coated overnight at 4 °C with 50 μl of 4 μg/ml anti-human/mouse CD42a Ab (MBS9206081, MyBioSource). After washing three times, the wells were blocked with 2% (w/v) BSA-PBS for 2 h. The wells were then incubated with lysate of human or mouse platelets for 2 h. After that, hybridoma supernatants or purified mAbs were added to the wells and incubated for 60 min. The bound antibodies were detected by HRP-conjugated goat anti-mouse IgG or goat anti-rat IgG. After the background signal had been subtracted, the binding curve was fitted to the eq. $Y = B_{max} \times [\text{ligand}]/(K_d + [\text{ligand}])$

where $Y$ is the specific binding, $[\text{ligand}]$ the ligand concentration, $B_{max}$ the binding maximum, and $K_d$ the equilibrium dissociation constant.
generated Fab fragment was purified using Protein A beads (6501-5, Biovision, CA, USA).

**Platelet activation**
Washed platelets (1.2 x 10^7 cells/ml) were treated with hybridoma supernatants or purified mAbs at room temperature (RT) for 20 min and detected with FITC or APC-conjugated antibody. Platelet activation induced by tumor cells was by adding 1 x 10^5 cells/100 μl tumor cells to 1.2 x 10^6 cells/100 μl washed platelets. When needed, the antibody was added to the platelets and incubated for at least 20 min before their stimulation by tumor cells. The signal of platelet activation was quantitated by the mean fluorescence intensity for the entire cell population (10,000 cells) on a Becton-Dickinson FACS Canto II instrument (BD Biosciences, San Jose, CA, USA).

**Platelet aggregometry**
Platelet-rich plasma (PRP) was generated as previously described [21]. The final platelet count in PRP was adjusted to 2.5 x 10^8 cells/ml. Aggregation was initiated in 300 μl of stirred PRP by the addition of noted agonists or 1 x 10^7 cells/50 μl MCF-7 cells to form the mixture of platelets and tumor cells. When required, the antibody was added to PRP and incubated for at least 5 min before stimulation with either agonists or tumor cells. Agonist-induced platelet aggregation was monitored in dual-channel Chrono-Log aggregometer (Havertown, PA, USA)

**Assay of tumor cells adhesion to platelets, platelet adhesion to endothelial cells, or tumor cell adhesion to endothelial cells**
The adhesion between tumor cells, platelets, and endothelial cells was measured as previously described [7].

**Animal experiments**

**Experimental lung metastasis assay**
In the Lewis lung carcinoma (LLC) model, 6-week-old C57BL/6J mice were randomly divided into six groups. There were eight mice per group, and half of the mice are male and half are female in each group. Female and male mice were separately cultured to avoid mating. For groups 1–6, mice were injected with LLC tumor cells (2.5 x 10^5 cells/mouse) with control IgG, control Fab, 2B4, 1D12, 2B4 Fab, or 1D12 Fab, respectively, at the dose of 50 μg/mouse through the lateral tail vain, along with the tumor cells. After 14 days, the lungs were removed, rinsed with PBS, and the number of metastatic foci on the lung surface was counted. The pulmonary lobes were subsequently kept in 4% paraformaldehyde for later paraffin embedding and hematoxylin and eosin staining. The same experiment was repeated using B16F10 melanoma mouse model (1 x 10^6 B16F10 cells/mouse).

**Spontaneous metastasis assay**
For spontaneous metastasis, 6-week-old BCLB/C female mice were subcutaneously injected with 1 x 10^5 4T1 tumor cells. The mice were treated with 50 μg/mouse 2B4, 2B4 Fab, 1D12, or 1D12 Fab, respectively, when the tumor volume reached 80 mm^3. After 3 weeks, the mice were killed, and the surface metastatic nodules on the lung were counted and the volume of primary tumor was recorded.

**Determination of mouse platelet count**
The platelet number was quantitated by a Becton-Dickinson FACS Canto II instrument equipped with BD Trucount Tubes (340334). The subsequent steps were then carried out by following the manufacturers’ instructions.

**Bleeding time**
The bleeding time was measured as previously described [22]. Briefly, the mouse tail vein was severed 2 mm from its tip and blotted every 30 s on a circular sheet of filter paper to obtain an objective measurement. Bleeding time was calculated when there was absence of blood on the filter paper. Bleeding time differences were recorded by an unbiased observer and confirmed by two other observers blinded to the experimental status of the mice.

**Statistical analysis**
Statistical analysis was performed using Prism 6 software. All experiments were carried out at least three times, and the results are presented as the mean ± standard deviation. Statistical significance was assessed by using the one-way analysis of variance (ANOVA) followed by Dunnett’s post hoc test. P values < 0.05 were considered statistically significant.

**Results**

**Generation and screening of mAbs targeting mouse platelet GPIIbα**
To generate antibodies that bind to mouse platelet GPIIbα, washed mouse platelet lysate was used as the antigen for rat immunization. Obtained hybridoma clones were screened in ELISA for binding affinity to the GPIIb-IX complex. Positive clones were further screened for their abilities to inhibit platelet-cancer cell adhesion (Additional file 1: Table S1A). After screening, we obtained six positive clones that could bind to GPIIb-IX complex (Fig. 1a) and inhibit platelet-tumor cell adherence to different extents (Additional file 2: Figure S1A). At static condition, two of the six antibodies, 2B4 and 1D12, had virtually no effect on the activation of integrin αIIbβ3, which is used to indicate platelet activation [21], while the other four could activate...
platelet to a certain degree in the same condition (Additional file 2: Figure S1B). Therefore, 2B4 and 1D12 were eventually selected for study.

Purified 2B4 and 1D12 (Additional file 2: Figure S1C) exhibited higher binding affinity to immobilized GPIb-IX complex than the negative control (Ctrl IgG) (Fig. 1b). The $K_d$ of 2B4 and 1D12 was $2.47 \pm 0.28$ and $9.62 \pm 0.52 \mu g/ml$, respectively. Like 2B4 and 1D12 antibodies, their Fab fragments exhibited strong binding affinity to fresh washed mouse platelets but not human platelets as

**Fig. 1** 2B4 and 1D12 specifically bind to mouse glycoprotein (GPI)ba. a Binding of rat anti-mouse antibodies to GPIb-IX complex was detected in ELISA. GPIb-IX was captured by anti-GPIX antibody which complex was immobilized in microtiter plates. Supernatant of hybridoma cells, each identified by the clone name, and the negative control, in the form of RPMI-1640 fetal bovine culture medium with 5 μg/ml rat IgG, were added to the coated wells. The bound Ab was detected with HRP-conjugated rabbit anti-rat IgG. ***P < 0.001. b Binding of 2B4 and 1D12 to GPIb-IX complex were detected in ELISA. Purified mAbs, colored as indicated, and negative controls, in the form of rat IgG, were added to the GPIb-IX immobilized microtiter plates. The bound Ab was detected with HRP-conjugated rabbit anti-rat IgG. c Binding of FITC-conjugated Fab to washed mouse platelets was detected in flow cytometry. Washed mouse platelets were incubated with each Fab at indicated concentration. Binding of Fab was detected by flow cytometry and quantitated by mean fluorescence intensity. d 2B4 and 1D12 specifically bound to mouse platelets. Washed human or mouse platelets were incubated with 10 μg/ml FITC-conjugated 2B4 or 1D12, respectively. Binding of Ab was detected by flow cytometry and quantitated by mean fluorescence intensity. e 2B4 and 1D12 recognized specifically GPIba in Western blot under nonreducing (n.r.) and reducing (r) conditions. Total lysates of mouse platelets were immunoblotted with either 2B4 or 1D12. Molecular weight marker (M) was shown and labeled in kDa on the left. f Binding of 5 μg/ml of 2B4 or 1D12 to indicated concentration of GPIba peptide fragments were detected in ELISA. GPIba peptide fragment was immobilized in microtiter plates. Indicated concentration antibodies were added to the coated wells. The bound Ab was detected with HRP-conjugated rabbit anti-rat IgG. Each figure or histogram is a representative of three independent experiments.
detected by flow cytometry using FITC-conjugated Fab (Fig. 1c, d). Immunoblotting of platelet lysate with 2B4 and 1D12 produced almost the same protein bands as those blotted with a commercialized well-documented anti-mouse GPIbα antibody (Fig. 1e). These results illustrated that 2B4 and 1D12 specifically recognize mouse GPIbα.

By using synthetic peptides, we obtained 20 purified recombinant GPIbα fragment (Additional file 3: Table S2B) to characterize the binding sites of 2B4 and 1D12. In ELISA, aa 277-290 showed the highest binding with 2B4; meanwhile, 1D12 bound to aa 41-50 (Additional file 4: Figure S2A and B), and the binding of the antibody to the peptide fragment was in a concentration-dependent...
Fig. 3 (See legend on next page.)
manner (Fig. 1f). Interestingly, SZ2 antibody was found binding to aa 268-282 GPIbα fragment in human platelet [23]; it therefore shares the similar binding site with that of 2B4 on mouse platelets (this was confirmed in this study shown in Additional file 4: Figure S2D). In addition, AK2 antibody recognized aa 36-59 GPIbα fragment in human platelet [24], therefore also overlapping the binding site with that of 1D12 on mouse platelet. Since previous experiments showed that vWF could bind to these two binding sites in GPIbα [25], we therefore speculated that 2B4 and 1D12 could also affect vWF binding.

**Anti-mouse GPIbα monoclonal antibodies 2B4 and 1D12 inhibit vWF binding**

To determine whether 2B4 and 1D12 affect vWF binding, we tested by flow cytometry using recombined mouse vWF. Figure 2a showed that both 2B4 and 1D12 inhibited vWF binding when platelet was activated by ristocetin (1 mg/ml). Since ristocetin-induced platelet aggregation is associated with vWF binding [26], we next investigated platelet aggregation induced by several agonists. 2B4 significantly inhibited ristocetin-induced platelet aggregation but did not affect the aggregation induced by ADP and thrombin (Fig. 2b). In addition, collagen-induced platelet aggregation was totally inhibited by 2B4. This is supportive to a previously reported study that the collagen-vWF-GPIbα axis was critical for platelet adhesion to a damaged blood vessel and the binding to collagen could be influenced when vWF binding is inhibited [27]. It is noteworthy, however, that 1D12 had no influence on neither ristocetin- nor collagen-induced aggregation. This is reminiscent of a previously reported antibody p0p1/1-5 [28] that affected vWF binding without influencing the aggregation induced by ristocetin and collagen. These might be because of the different binding epitopes. Nonetheless, our data in Fig. 2a demonstrated clearly that 2B4 and 1D12 could inhibit vWF binding.

**2B4 and 1D12 inhibit tumor metastasis in vivo and in vitro**

To investigate whether the inhibition of vWF-GPIbα interaction was associated with tumor metastasis, we first investigated the effect of antibodies on the interaction between platelets and hypoxic-treated LCC cells in vitro. The left panel of Fig. 3a demonstrated that platelet-LLC adhesion was significantly decreased with a maximum of approximately 60% inhibition when platelets were pretreated with 2B4 or 1D12. A similar result was observed using platelets from tumor-bearing mice (Fig. 3b). Because vWF-GPIbα and vWF-collagen interactions play a critical role in the adhesion of platelets to the endothelial cells [29], we therefore reasoned that 2B4 and 1D12 could inhibit the adhesion between platelets and endothelial cells. The middle panel in Fig. 3a showed that platelet adhesion to hypoxic-treated HUVECs was reduced in a dose-dependent manner after incubation with 1D12 or 2B4. Meanwhile, the adhesion of BCECF-labeled hypoxic-treated LLC cells to hypoxic-treated HUVECs was also markedly decreased when platelets were pretreated with 2B4 or 1D12 (Fig. 3a, right panel). As expected, the negative control, normal rat IgG had no effect.

We further investigated the inhibitory effect of these antibodies in vivo using an experimental metastasis model with female C57BL/6j mice. As noted in Fig. 3c, the melanoma cells B16F10 co-incubated with either 2B4 or 1D12 (or their Fabs) resulted in a markedly decreased number of surface pulmonary nodules compared to the control group using ctrl IgG or its Fab. The same phenomenon was observed when using LLC cells (Fig. 3d). This finding was again confirmed by counting the metastatic lesions under microscopy using the H-E slides of the lung tissue (Fig. 3e). In addition, in vivo experimental metastasis assay with male mice also showed inhibition of tumor metastasis by antibodies (data not shown). Moreover, in the spontaneous metastasis model, the body weight and the volume of primary tumor was
not be influenced by antibody injection (Fig. 4a–c), but the lung metastasis was obviously suppressed (Fig. 4d). All together, these data suggested 2B4 and 1D12 could potently inhibit the adhesion of cancer cells in vitro and metastasis in vivo.

**2B4 and 1D12 have no effect on platelet activation and hemostatic function**

Since platelet activation and subsequent clearing induced by antibodies targeting GPIbα limited the clinical application of previous platelet antibodies in suppressing cancer metastasis [18, 30], it is therefore important to investigate whether 2B4 and 1D12 could affect platelet activation and/or induce thrombocytopenia in vivo. Treatment of washed mouse platelets with 2B4 or 1D12 did not induce increased expression of P-selectin (Fig. 4e). Furthermore, the addition of 2B4 or 1D12 to PRP did not induce platelet aggregation (Fig. 4f). Injection of 2B4 or 1D12 at the dose of 50 μg/mouse did not affect tail-bleeding time (Fig. 4g). While the injection of 2B4 or 1D12 decreased almost 40% of the platelet count, that of their respective Fab fragments did not change the platelet count (Fig. 4h, i). Therefore, 2B4 and 1D12 can potentially suppress cancer metastasis without significantly affecting the number and function of platelets.

**Generation and characterization of mouse anti-human platelet GPIbα monoclonal antibody YQ3**

Based on the above findings, we then decided to use the same approach to generate a series of mouse anti-human platelet GPIbα monoclonal antibodies to explore the role of human GPIbα in cancer metastasis (Additional file 1: Table S1B). After screening, we obtained a potent antibody, YQ3, as the best candidate for the subsequent studies. Our screening results showed that compared to other candidates, YQ3 exhibited the strongest binding affinity to GPIb-IX complex (Fig. 5a) and inhibitory effect on adhesion (Additional file 2: Figure S1D).

Further experiments illustrated that purified YQ3 (Additional file 2: Figure S1E) exhibited strong binding to immobilized GPIb-IX complex in a dose-dependent manner (Fig. 5b, Kd of YQ3 is 2.26 ± 0.37 μg/mL). Meanwhile, it specifically recognized human but not mouse platelet GPIbα (Fig. 5c–e). By using 20 purified human GPIbα fragments (Additional file 3: Table S2A) in ELISA, we found that YQ3 bound to aa 31-56 and aa 277-290 of human GPIbα in a dose-dependent manner. (Fig. 5f left panel, Additional file 4: Figure S2C). These two binding sites overlapped those of the above-mentioned two rat anti-mouse antibodies. In addition, the Fab of YQ3 was found to bind to aa 41-56 and aa 277-286 (Fig. 5f right panel, Additional file 4: Figure S2E). To further verify the accuracy of the binding sites, we conducted a competitive binding assay. Briefly, washed human platelets were pretreated with aa41-55 or aa277-286, or both peptides before adding FITC-conjugated YQ3 Fab. As expected, peptides aa 41-56 and aa 277-286 inhibited 50% binding of YQ3 Fab to platelets. When aa 41-56 or aa 277-286 was used alone, such binding was also impaired, but to a lesser degree (Fig. 5g).

**YQ3 inhibits adhesion and cancer cell-induced platelet activation**

We next investigated whether YQ3 could affect vWF binding. Figure 6a showed that vWF binding induced by ristocetin in vitro was decreased when incubated with YQ3. Meanwhile, ristocetin- and collagen-induced aggregation were also significantly inhibited by YQ3 and its Fab fragment. However, ADP and thrombin-induced aggregation was not influenced (Fig. 6b).

To investigate inhibitory potential of YQ3 in cancer metastasis, we first tested YQ3 on TCIPA. Figure 6c showed that platelet aggregation induced by breast cancer cells MCF-7 was partially inhibited by the addition of YQ3. We then tested the effect of YQ3 on adhesions between platelet, tumor cells (e.g., colorectal cancer
Fig. 5 (See legend on next page.)
HCT116), and HUVECs. Figure 6d showed that YQ3 inhibited cell adhesion between HCT116 cells and platelets, platelets and HUVECs, and HUVECs and HCT116 cells. Similar results were observed when we used other tumor cell lines such as breast cancer MDA-MB-231 and lung cancer A549 cells (data not shown).

We then tested the effect of YQ3 on tumor cell-induced platelet activation. Different types of tumor cells (e.g., HCT116, A549, and MDA-MB-231) were incubated with platelet with or without YQ3. The expression of P-selectin was used to indicate the degree of platelet activation. Again, YQ3 was found able to inhibit tumor cell-induced platelet activation (Fig. 6e). These results together suggested that YQ3 might have the potential to inhibit metastasis.

**YQ3 inhibits the adhesion between patients’ platelets and tumor cells without accelerating platelet clearance**

We next tested the effect of YQ3 using patients’ blood. Pre-incubated platelets collected from lung cancer patients (patients II and III had no metastasis; patients IV–VII presented with metastasis) with YQ3 Fab dramatically attenuated their adhesion to A549 cells (Fig. 7a, b). It is therefore supportive to our previous finding that YQ3 inhibited the adhesion between platelets and tumor cells. Moreover, while the expression levels of GPIbα were higher in lung cancer patients than in healthy controls, no difference was found between patients with metastasis and without, suggesting the expression level of GPIbα could not be correlated to the progression of cancer metastasis (Fig. 7c).

We then tested whether in patients’ blood, YQ3 could affect platelet activation or platelet count. Figure 7d demonstrated that YQ3 did not induce PRP aggregation. Moreover, treatment of washed human platelets with YQ3 did not induce activation of integrin αIIbβ3 or increase the expression of P-selectin (Fig. 7e). To explore the effect of YQ3 on platelet count, hTg mice were treated with YQ3 or YQ3 Fab, and platelet count was monitored over a 4-day period after injection. Figure 7f showed that the injection of YQ3 induced severe decrease of platelet count, but its Fab did not. Therefore, mouse anti-human GPIbα monoclonal antibody YQ3 will likely not have concerning bleeding complications, and it is worth a further exploration in humanized models.

**Discussion**

Multiple studies have shown that the platelet GPIbα is an important receptor in the process of tumor metastasis [9, 18, 31, 32]. However, the biggest obstacle to use GPIbα inhibition for cancer treatment is potential severe bleeding complications. This is even more concerning when conventional chemotherapy is used since it almost universally affects platelet count. However, several antibodies specifically targeting platelet GPIbα and inhibiting vWF binding to platelet were reported not to influence the platelet count dramatically [33–35]. Nancy et al. investigated the anti-thrombotic effect of human GPIbα mAb 6B4 Fab fragment in vivo and found that through inhibition of the binding of vWF to GPIbα, fewer platelets were activated, resulting in decreased risk of bleeding [33]. Similarly, the anti-human vWF monoclonal antibody SZ-123 was found to inhibit vWF-collagen and vWF-platelet interactions in vivo and did not significantly prolong bleeding time [34, 35]. These findings are important considering inhibition of collagen-vWF-GPIbα axis is therefore considered as a new strategy in anti-thrombotic therapy [29]. Nevertheless, contradictory findings were reported that vWF deficiency could promote tumor metastasis instead [36]. It remains debatable whether this was due to enhanced platelet GPIbα availability that promoted metastasis in the absence of vWF. If this is the case, then inhibiting the interactions among collagen, vWF, and GPIbα might be valuable. Indeed, in this study, we have confirmed such strategy is useful with minimal effect on platelet number and function.
Fig. 6 (See legend on next page.)
Compared with traditional anti-platelet drugs, which prevent thrombosis by inhibiting normal platelet function, the monoclonal antibodies developed in this study utilize a different mechanism of action. In our report, we developed two novel rat anti-mouse GPIbα monoclonal antibodies, 2B4 and 1D12, and a mouse anti-human GPIbα monoclonal antibody YQ3. These antibodies exhibited inhibitory potential on cancer metastasis by blocking the vWF-GPIbα axis without affecting platelet activation and hemostatic function. Therefore, we proved that it is possible to use antibodies to inhibit metastasis without inducing thrombocytopenia by blocking the vWF-GPIbα interaction.

Several anti-GPIbα monoclonal antibodies which inhibit vWF binding to platelet have already been developed, these include p0p/B [9, 28], SZ2 [23], AK2 [24], and VM16d [37]. Luis et al. [9] investigated the effect of Fab fragment of p0p/B, a mAb directed against the vWF-binding site on mouse GPIbα, on pulmonary metastasis. An unexpected increase in experimental metastasis after blockade of GPIbα was observed. The mechanism of p0p/B promotion on metastasis was thought that the blockade of GPIbα by p0p/B led to the decrease in platelet interaction with P-selectin, which then resulted in increased availability of P-selectin for the direct interaction of cancer cells with endothelium cells. In comparison, in our study, 1D12 and 2B4 were found to inhibit metastasis likely due to their capacity of inhibiting the vWF-GPIbα interaction. Therefore, despite using GPIbα as the same target, using antibodies binding to different sites of GPIbα, hence affecting its binding partners through the resultant spatial conformations, distinct influence on cancer metastasis could be observed.

Interestingly, the binding site of our YQ3 overlaps the previously reported monoclonal antibody SZ2, which binds to vWF-binding site aa 268-282 on mouse GPIbα [23]. Leslie et al. [38] reported previously that MCF-7-induced platelet aggregation was inhibited by 46% when tumor cells were pretreated with SZ2. However, SZ2 failed to affect the extent of platelet-LS174T cell hetero-aggregation [39]. Furthermore, the human GPIbα monoclonal antibody AK2 [24], which has an overlap-binding site aa 41-55 with YQ3, was not reported on its effect on metastasis. Based on the above reports, we tested the effect of YQ3 on platelet-mediated BCECF-labeled HCT116 cells adhesion to HUVECs. Right panel, the effect of YQ3 on platelet-mediated BCECF-labeled HCT116 cells adhesion to HUVECs in vitro. YQ3 inhibited tumor cell-induced platelet activation. Fifty microliters of different tumor cell (HCT116, A549, or MDA-MB-231) suspension with $1 \times 10^5$ cells/ml was added to washed platelet. Platelet was pretreated with 10 μg/ml YQ3 for 5 min. Aggregation was detected for 13 min. d YQ3 inhibited platelet, HCT 116 cell, and endothelial cell adhesion between each other. Left panel, the quantitative analysis of adhesion of HCT116 with BCECF-labeled platelet in the presence of various concentration of YQ3. Middle panel, the effect of YQ3 on the adhesion of BCECF-labeled platelets to HUVECs. Right panel, the effect of YQ3 on platelet-mediated BDECF-labeled HCT116 cells adhesion to HUVECs in vitro. e YQ3 inhibited tumor cell-induced platelet activation. Fifty microliters of different tumor cell (HCT116, A549, or MDA-MB-231) suspension with $1 \times 10^5$ cells/ml was added to washed platelet. Platelet was pretreated with 10 μg/ml YQ3 or negative control (normal mouse IgG). Platelet activation was detected by APC-conjugated P-selectin Ab. The histograms are representative of three independent experiments.

It is interesting that injection of YQ3 full-length antibody to hTg mice induced severe thrombocytopenia similar to the traditional anti-platelet drugs, but injection of Fab fragment alone did not. Such phenomenon might be explained by a recently proposed theory that anti-GPIbα antibodies harboring bivalent structure may exert a pulling force on platelet GPIbα by crosslinking platelets under shear flow [30]. The bivalent structure of YQ3 full-length antibody could therefore exert pulling force to induce platelet clearing, while the univalent structure of YQ3 Fab will
Fig. 7 (See legend on next page.)
We therefore demonstrated the role of GPIb in promoting tumor metastasis and found a new target for the inhibition of tumor metastasis.

**Conclusion**

In summary, we obtained two novel rat anti-mouse GPIbα antibodies, 1D12 and 2B4, and a mouse anti-human GPIbα antibody YQ3. All of antibodies have a potential effect on inhibition of tumor metastasis by affecting the collagen, vWF, and GPIbα interaction via binding to GPIbα aa 41-50 and aa 277-290, respectively. We therefore demonstrated the role of GPIbα in promoting tumor metastasis and found a new target for the inhibition of tumor metastasis.

---

Additional files

**Additional file 3: Table S2.** Characterization of antibodies’ binding sites. Mouse platelet GPIbα fragments bound to (A) 2B4 and (B) 1D12. Human platelet GPIbα fragments bound to (C) YQ3, (D) S22 and (E) YQ3 Fab. 20 μg/ml platelet GPIbα fragment was immobilized in microtiter plates. Ten micrograms per milliliter of antibody was added to the coated wells, respectively. (F) S22 did not affect adhesion of A549 lung cancer cells to patients’ platelets. The adhesion of A549 to patients’ platelets pretreated with 10 μg/ml S22 as observed under fluorescence microscope. IV/IV/III: patients with metastasis; IV/IV/II: patients without metastasis; IV/II/II: patients with metastasis. The quantitative analysis of adhesion was shown in b. *P value is indicated; **P < 0.01; ***P < 0.001.

---

Abbreviations

GPIbα: Platelet glycoprotein Ibα; mAb: Monoclonal antibodies; TCIPA: Tumor cell-induced platelet aggregation; vWF: von Willebrand factor
Acknowledgements
We thank Dr. Zhenghua Wu and Prof. Dawei Li at Shanghai Jiao Tong University School of Pharmacy and Dr. Wei Deng at Emory University for their technical support.

Funding
This work was supported by the National Natural Science Foundation of China (No. 81502540) and Fundamental Research Fund for the Central Universities of China (No. 22201514333). This work was also partially supported by the University of Iowa Start-up Funds (J.Z.), as well as the Grant R01-15-176-40 from the American Cancer Society, administered through The Holden Comprehensive Cancer Center at The University of Iowa (J.Z.).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
YQ, JK, JL, and XL designed the research. YQ, WC, XYL, XG, and XF performed the research and analyzed results. FW, SR, and JLL provided the critical reagents. YQ, KX, and XL wrote the paper. JZ, RL, and JWL edited the manuscript and provided critical comments. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Animal experiments were conducted in mice or rats using protocols approved by the IACUC of Putuo Hospital. Written, informed consent was obtained from all blood donors prior to their inclusion in studies.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1State Key Laboratory of Bioreactor Engineering & Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Meilong Rd, Shanghai 200237, People’s Republic of China. 2Affic Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, 30322, USA. 3Central laboratory, General Surgery, Putuo Hospital, and Interventional Cancer Institute of Chinese Integrative Medicine, Shanghai University of Traditional Chinese Medicine, 164 Lanli Rd, Shanghai 200062, People’s Republic of China. 4Department of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, People’s Republic of China. 5Department of Biotechnology and Molecular Cell Biology, Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People’s Republic of China. 6Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA.

Received: 4 April 2018 Accepted: 31 August 2018
Published online: 17 September 2018

References
1. Wojtkiewicz MZ, Hempel D, Sierko E, Tucker SC, et al. Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past? Cancer Metastasis Rev. 2017;36:1–25.
2. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9:237.
3. Ikeeda M, Furukawa H, Inamura H, Shimizu J, et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 2002;9:287–91.
4. Monreal M, Fernandezlammazares J, Pihol M, Julian JF, et al. Platelet count and survival in patients with colorectal cancer—a preliminary study. Thromb Haemost. 1998;79:916.
5. Symbas NP, Townsend MF, Bigalley R, Keane TE, et al. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. British Journal of Urology International. 2001;87:715–6.
6. Güer F, Moser F, Tamussino K, Reich D, et al. Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol Oncol. 1998;70:210–4.
7. Zhang W, Dang S, Hong T, Tang J, et al. A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment. Blood. 2012;120:2889–98.
8. Poggi A, Wenzl E, Ciocco V, Wasteson A. Platelet contribution to cancer cell growth and migration: the role of platelet growth factors. Pathophysiol Haemost Thromb. 1988;18:18–28.
9. Erpenbeck L, Nieswandt B, Schön M, Pozgajova M, et al. Inhibition of platelet GP Ibα and promotion of melanoma metastasis. J Invest Dermatol. 2010;130:576–86.
10. Amirkhosravi A, Mousa SA, Aranya M, Blaydes S, et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GP IIb/IIIa antagonist XV454. Thromb Haemost. 2003;89:549–54.
11. Trikha M, Zhou Z, Timar J, Raso E, et al. Multiple roles for platelet GP IIb/IIIa and alphavbeta3 integrin in tumor growth, angiogenesis, and metastasis. Cancer Res. 2002;62:2824–33.
12. Nardi M, Feinmann SJ, Hu L, Li Z, et al. Complement-independent Ab-induced peroxide lysis of platelets requires 12-lipoxygenase and a platelet NADPH oxidase pathway. J Clin Invest. 2004;113:973–80.
13. Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Anticancer Res. 2010;30:2362–7.
14. Terrabue V, Max I, Denis CV. Role of von Willebrand factor in tumor metastasis. Thromb Res. 2007;120 Suppl 2:2564.
15. Chen M, Geng JG. P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp. 2006;54:75–84.
16. Nierodzik ML, Plotkin A, Kajumo F, Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest. 1991;87:229–36.
17. Lof A, Müller JP, Brehm MA. A biophysical view on von Willebrand factor activation. J Cell Physiol. 2017;232:799–810.
18. Jain S, Zuker M, Liu J, Russell S, et al. Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proc Natl Acad Sci U S A. 2007;104:40924.
19. Ware J, Russell S, Ruggeri ZM. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci U S A. 2000;97:2803.
20. Köhler G, Milstein C, Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Biotechnology. 1975;2:524.
21. Liang X, Russell SR, Estelle S, Jones LH, et al. Specific inhibition of ectodomain shedding of glycoprotein Ibα by targeting its juxtamembrane shedding cleavage site. J Thromb Haemost. 2013;11:2155–62.
22. Chen W, Liang X, Syed AK, Jessup P, et al. Inhibiting GPIbαβa shedding preserves post-transfusion recovery and hemostatic function of platelets after prolonged storage. Arterioscler Thromb Vasc Biol. 2016;36:1821–8.
23. Cauwenberghs N, Vanhoorebeke K, Vauterin S, Westra DF, et al. Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibαβa reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibαβa. Blood. 2001;98:652.
24. Ward CM, Andrews RK, Smith AI, Berndt MC. Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibαβa. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibalpha. British Journal of Urology International. 2001;87:652.
25. Ruan CG, Du XP, Xi XD, Castaldi PA, et al. A murine anticytgp Ibαβa monoclonal antibody, SZ 2, inhibits platelet aggregation induced by both ristocetin and collagen. Blood. 1987;69:570–7.
26. Li C, Piran S, Chen P, Lang S, et al. The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. The Journal of clinical investigation. 2011;121:4537–47.
27. Wu D, Vanhoorelbeke K, Cauwenberghs N, Meiring M, et al. Inhibition of the von Willebrand (WF)-collagen interaction by an antihuman WFα monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood. 2002;99:3623–8.
28. Bergmeier W, Rackebrandt K, Schöder W, Zirmiglb H, et al. Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. Blood. 2000;95:886–93.
29. Vanhoorelbeke K, Ulrichts H, Schoolmeester A, Deckmyn H. Inhibition of platelet adhesion to collagen as a new target for antithrombotic drugs. Curr Drug Targets Cardiovasc Haematol Disord. 2003;3:125–40.
30. Quach ME, Dragovich MA, Chen W, Syed AK, et al. Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets. Blood. 2017;131:787–96. blood-2017-05-784975
31. Jain S, Russell S, Ware J. Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. J Thromb Haemost. 2009;7:1713–7.
32. Karpatkin S, Pearlstein E, Ambrogio C, Coller BS. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Investig. 1988;81:1012–9.
33. Cauwenberghs N, Meiring M, Vauterin S, van Wyk V, et al. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol. 2000;20:1347–53.
34. Zhao YM, Liang M, Ji SD, He Y, et al. Anti-human VWF monoclonal antibody SZ-123 prevents arterial thrombus formation by inhibiting VWF-collagen and VWF-platelet interactions in Rhesus monkeys. Biochem Pharmacol. 2013;85:945–53.
35. Zhao Y, Dong N, Shen F, Xie L, et al. Two novel monoclonal antibodies to VWF Ab3 inhibit VWF-collagen and VWF-platelet interactions. J Thromb Haemost. 2007;5:1963–70.
36. Terraube V, Pendu R, Baruch D, Gebbink MF, et al. Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost. 2006;4:519.
37. Mazurov AV, Vinogradov DV, Vlasik TN, Repin VS, et al. Characterization of an antiglycoprotein Ib monoclonal antibody that specifically inhibits platelet-thrombin interaction. Thromb Res. 1991;62:673–84.
38. Olekowicz L, Mrowiec Z, Schwartz E, Khordobi M, et al. Characterization of tumor-induced platelet aggregation: the role of immunorelated GP Ib and ja: math expression by MCF-7 breast cancer cells. Thromb Res. 1995;79:261.
39. McCarty OJ, Jadhav S, Burdick MM, Bell WR, et al. Fluid shear regulates the kinetics and molecular mechanisms of activation-dependent platelet binding to colon carcinoma cells. Biophys J. 2002;83:836–48.
40. Leclerc JR. Platelet glycoprotein Ib/IIa antagonists: lessons learned from clinical trials and future directions. Crit Care Med. 2002;30:332–40.
41. Palumbo JS, Kombirch KW, Drew AF, Grimes TS, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96:3302.